Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cornus officinalis triterpenoid tablet
- Development stage
- Phase 1
- Lead developer
- Cinkate
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cornus officinalis triterpenoid tablet is a botanical drug candidate developed by Suzhou Changzheng-Xinkai Pharmaceutical for the treatment of type 2 diabetes mellitus. The drug is a tablet formulation containing the total triterpenoid fraction extracted from the fruit of *Cornus officinalis* (Shan Zhu Yu), a plant widely used in traditional Chinese medicine. Triterpenoids from this species, including compounds like ursolic acid and oleanolic acid, have been investigated for their ability to regulate glucose metabolism and improve insulin sensitivity. Preclinical research suggests these effects may be mediated through the inhibition of protein tyrosine phosphatase 1B (PTP1B) and the activation of the AMPK signaling pathway. The drug has undergone Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, intended to support further development for patients with early-stage, mild type 2 diabetes.
- Other names
- Cornus officinalis total triterpenoid tabletsShan Zhu Yu Zong San Tie Pian
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)
Beyond the preview
Go deeper on Cornus officinalis triterpenoid tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cornus officinalis triterpenoid tablet.